Stock listing
NASDAQ:HUMA Humacyte, Inc. Stock
Home listing (NASDAQ) of Humacyte, Inc.
Follow Humacyte, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:HUMA
$0.445 USD -0.055 (-10.9%)
Close on Nov 20, 2026
- Day range
- $0.444 – $0.520 USDNov 20, 2026
- Volume
- 5.77M sharesNov 20, 2026
- Market cap
- $123.7M USDAt the close on Nov 20, 2026 · price × 277.8M shares outstanding
- 52-week range
- $0.337 – $1.525 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2.80M USDMedian day 4.63M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:HUMA · Home | $0.445 USD | -0.055 (-10.9%) | 5,771,034 | $0.513 | $0.520 | $0.444 | $0.500 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:HUMA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.445 | -0.055 | -10.9% | $0.513 | $0.520 | $0.444 | 5,771,034 | |
| $0.500 | -0.001 | -0.2% | $0.505 | $0.529 | $0.485 | 3,906,847 | |
| $0.501 | -0.039 | -7.3% | $0.540 | $0.575 | $0.501 | 4,343,121 | |
| $0.540 | -0.018 | -3.2% | $0.556 | $0.578 | $0.525 | 3,043,482 | |
| $0.558 | -0.037 | -6.2% | $0.600 | $0.610 | $0.535 | 4,625,129 | |
| $0.595 | +0.004 | +0.6% | $0.587 | $0.630 | $0.563 | 5,229,709 | |
| $0.592 | +0.002 | +0.3% | $0.587 | $0.626 | $0.554 | 6,778,329 | |
| $0.590 | +0.135 | +29.6% | $0.500 | $0.597 | $0.492 | 15,666,482 | |
| $0.455 | +0.007 | +1.6% | $0.450 | $0.493 | $0.450 | 5,663,214 | |
| $0.448 | +0.052 | +13.1% | $0.410 | $0.449 | $0.400 | 5,152,000 | |
| $0.396 | -0.054 | -12.0% | $0.440 | $0.449 | $0.387 | 6,011,900 | |
| $0.450 | +0.009 | +2.0% | $0.460 | $0.475 | $0.425 | 2,641,900 | |
| $0.441 | +0.043 | +10.8% | $0.405 | $0.445 | $0.391 | 3,203,400 | |
| $0.398 | -0.013 | -3.2% | $0.424 | $0.432 | $0.385 | 5,214,400 | |
| $0.411 | -0.059 | -12.6% | $0.460 | $0.460 | $0.400 | 5,119,900 | |
| $0.470 | 0.000 | 0.0% | $0.473 | $0.510 | $0.460 | 3,704,500 | |
| $0.470 | +0.024 | +5.4% | $0.450 | $0.479 | $0.432 | 2,657,500 | |
| $0.446 | +0.045 | +11.2% | $0.414 | $0.464 | $0.394 | 3,715,700 | |
| $0.401 | -0.034 | -7.8% | $0.460 | $0.462 | $0.391 | 3,975,300 | |
| $0.435 | +0.022 | +5.3% | $0.420 | $0.440 | $0.399 | 2,607,700 | |
| $0.413 | +0.002 | +0.5% | $0.410 | $0.420 | $0.400 | 2,252,100 | |
| $0.411 | +0.005 | +1.2% | $0.410 | $0.420 | $0.392 | 4,174,100 | |
| $0.406 | +0.005 | +1.2% | $0.392 | $0.416 | $0.390 | 4,884,200 | |
| $0.401 | -0.028 | -6.5% | $0.428 | $0.439 | $0.391 | 4,691,500 | |
| $0.429 | -0.011 | -2.5% | $0.450 | $0.460 | $0.420 | 5,962,100 | |
| $0.440 | +0.086 | +24.3% | $0.366 | $0.446 | $0.351 | 20,787,000 | |
| $0.354 | -0.005 | -1.4% | $0.363 | $0.379 | $0.337 | 5,431,100 | |
| $0.359 | -0.031 | -7.9% | $0.390 | $0.391 | $0.356 | 12,348,200 | |
| $0.390 | -0.015 | -3.7% | $0.400 | $0.413 | $0.387 | 16,347,100 | |
| $0.405 | -0.042 | -9.4% | $0.440 | $0.449 | $0.391 | 8,597,900 | |
| $0.447 | -0.025 | -5.3% | $0.475 | $0.480 | $0.437 | 5,485,200 | |
| $0.472 | -0.006 | -1.3% | $0.479 | $0.480 | $0.460 | 3,908,900 | |
| $0.478 | -0.022 | -4.4% | $0.501 | $0.510 | $0.472 | 4,281,100 | |
| $0.500 | -0.022 | -4.2% | $0.520 | $0.522 | $0.485 | 6,449,400 | |
| $0.522 | +0.019 | +3.8% | $0.506 | $0.534 | $0.503 | 5,395,400 | |
| $0.503 | -0.015 | -2.9% | $0.520 | $0.528 | $0.501 | 2,995,300 | |
| $0.518 | -0.015 | -2.8% | $0.540 | $0.548 | $0.510 | 5,739,900 | |
| $0.533 | -0.014 | -2.6% | $0.549 | $0.550 | $0.531 | 3,610,700 | |
| $0.547 | -0.010 | -1.8% | $0.550 | $0.569 | $0.532 | 4,959,200 | |
| $0.557 | -0.012 | -2.1% | $0.560 | $0.571 | $0.550 | 2,618,600 | |
| $0.569 | +0.003 | +0.5% | $0.560 | $0.573 | $0.543 | 2,833,900 | |
| $0.566 | -0.017 | -2.9% | $0.588 | $0.588 | $0.556 | 3,431,600 | |
| $0.583 | -0.007 | -1.2% | $0.588 | $0.608 | $0.581 | 3,468,900 | |
| $0.590 | +0.004 | +0.7% | $0.600 | $0.610 | $0.575 | 3,405,200 | |
| $0.586 | +0.011 | +1.9% | $0.570 | $0.608 | $0.570 | 6,987,700 | |
| $0.575 | +0.005 | +0.9% | $0.595 | $0.598 | $0.565 | 2,900,300 | |
| $0.570 | +0.018 | +3.3% | $0.558 | $0.596 | $0.550 | 4,955,300 | |
| $0.552 | -0.009 | -1.6% | $0.560 | $0.570 | $0.540 | 3,209,700 | |
| $0.561 | -0.007 | -1.2% | $0.550 | $0.575 | $0.550 | 3,160,900 | |
| $0.568 | +0.001 | +0.2% | $0.576 | $0.588 | $0.559 | 2,255,200 | |
| $0.567 | -0.012 | -2.1% | $0.580 | $0.580 | $0.560 | 2,661,200 | |
| $0.579 | -0.016 | -2.7% | $0.591 | $0.600 | $0.575 | 2,917,400 | |
| $0.595 | -0.010 | -1.7% | $0.610 | $0.610 | $0.580 | 2,402,000 | |
| $0.605 | +0.009 | +1.5% | $0.591 | $0.610 | $0.583 | 2,961,900 | |
| $0.596 | -0.001 | -0.2% | $0.608 | $0.610 | $0.584 | 3,016,700 | |
| $0.597 | +0.027 | +4.7% | $0.571 | $0.611 | $0.570 | 5,175,500 | |
| $0.570 | -0.031 | -5.2% | $0.598 | $0.601 | $0.570 | 16,536,100 | |
| $0.601 | -0.049 | -7.5% | $0.650 | $0.650 | $0.584 | 13,537,600 | |
| $0.650 | -0.043 | -6.2% | $0.690 | $0.695 | $0.640 | 4,916,000 | |
| $0.693 | +0.011 | +1.6% | $0.700 | $0.708 | $0.687 | 2,961,800 | |
| $0.682 | -0.019 | -2.7% | $0.710 | $0.712 | $0.670 | 5,677,000 | |
| $0.701 | +0.039 | +5.9% | $0.663 | $0.730 | $0.660 | 5,920,952 | |
| $0.662 | +0.020 | +3.1% | $0.675 | $0.694 | $0.642 | 3,758,871 | |
| $0.642 | -0.039 | -5.7% | $0.674 | $0.700 | $0.635 | 9,360,200 | |
| $0.681 | -0.054 | -7.3% | $0.707 | $0.715 | $0.663 | 6,648,200 |
- Ticker
- NASDAQ:HUMA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 19, 2026
Humacyte Submits Supplemental Biologics License Application to FDA for the Acellular Tissue Engineered Vessel in Dialysis Access
Latest earnings call · Nov 10, 2026
Humacyte (NASDAQ:HUMA) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Jun 10, 2026
Investor Presentation (June 2026)
Investor deck · 55 slides
Latest news
Humacyte Submits Supplemental Biologics License Application to FDA for the Acellular Tissue Engineered Vessel in Dialysis Access
Nov 19, 2026
Closed $0.445 (-10.9%) on Nov 20, 2026
Humacyte Presents Long-Term Clinical Data Demonstrating Low Atherosclerosis Susceptibility in Acellular Tissue Engineered Vessel
Nov 16, 2026
Closed $0.54 (-3.2%) on Nov 16, 2026
Five Presentations, One Leading Innovation: Humacyte’s Acellular Tissue Engineered Vessel Takes Center Stage at VEITH 2026
Nov 11, 2026
Closed $0.592 (+0.3%) on Nov 11, 2026
Humacyte Reports Third Quarter 2026 Results, Highlighted by More Than Doubling Symvess Revenue and Expanding Commercial Adoption
Nov 10, 2026
Closed $0.59 (+29.6%) on Nov 10, 2026
Humacyte Highlights First-in-Human Coronary Bypass Study at American Heart Association Scientific Sessions 2026
Nov 9, 2026
Closed $0.455 (+1.6%) on Nov 9, 2026
Humacyte Innovative Research in Coronary Bypass and Vascular Regeneration to be Highlighted at American Heart Association Scientific Sessions 2026
Nov 3, 2026
Closed $0.441 (+10.8%) on Nov 3, 2026
Humacyte To Announce 2026 Third Quarter Financial Results and Provide Business Update on November 10, 2026
Nov 2, 2026
Closed $0.398 (-3.2%) on Nov 2, 2026
Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues
Oct 28, 2026
Closed $0.47 (+5.4%) on Oct 28, 2026
Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner
Oct 23, 2026
Closed $0.435 (+5.3%) on Oct 23, 2026
Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals
Oct 15, 2026
Closed $0.44 (+24.3%) on Oct 15, 2026
Humacyte, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 45 in the last 12 months · 141 in all · newest Nov 19, 2026 · oldest 2021
- Calls
- 20 calls with a replay · 20 with a transcript · latest Nov 10, 2026
- Decks
- 8 decks · latest Jun 10, 2026
Where Humacyte, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:HUMA · Home listing · This page | NASDAQ | United States | USD |
| BOATS:HUMA | BOATS | United States | USD |
Valuation
EV/sales 40.1× against a median of 7.8×: 5th lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $96.01M USD
- P/E
- Loss
- EV/sales
- 40.1×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 6.8×
- Gross margin
- −549.8%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 2.0×
- Beta vs S&P 500
- 2.56
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Humacyte, Inc. · NASDAQ:HUMA | US$123.7M | US$96.01M | n/a | 40.1× | n/a | 6.8× | n/a | 2.0× | 2.56 |
| Yoda Pharmaceuticals Inc. · TPEX:7829 | US$127.1M | US$94.39M | n/a | n/a | n/a | 3.9× | n/a | 0.0× | n/a |
| UnicoCell Biomed Co., Ltd. · TWSE:6794 | US$126.3M | US$106.5M | n/a | 117× | n/a | 5.1× | −381.5% | 0.1× | n/a |
| MacroGenics, Inc. · NASDAQ:MGNX | US$125.3M | −US$127.6M | n/a | −0.9× | n/a | 5.0× | −34.6% | 1.4× | 0.83 |
| PolyPid Ltd. · NASDAQ:PYPD | US$124.3M | US$119.3M | n/a | n/a | n/a | 23.1× | n/a | 0.3× | 0.93 |
| Compass Therapeutics, Inc. · NASDAQ:CMPX | US$123.9M | −US$29.89M | n/a | n/a | n/a | 0.9× | n/a | 0.1× | 1.22 |
| Biomm SA · BMFBOVESPA:BIOM3 | US$123.5M | US$137.5M | 18.4× | 2.1× | 12.3× | 2.2× | 10.3% | 0.3× | n/a |
| Invivyd, Inc. · NASDAQ:IVVD | US$122.0M | US$3.86M | n/a | 0.1× | n/a | 0.8× | −214.8% | 0.1× | 2.06 |
| Satellos Bioscience Inc · TSX:MSCL | US$121.9M | US$69.24M | n/a | n/a | n/a | 2.5× | n/a | 0.0× | 0.49 |
| Alar Pharmaceuticals Inc · TPEX:6785 | US$121.0M | US$51.67M | n/a | 568× | n/a | 1.7× | n/a | 0.0× | n/a |
| CANbridge Pharmaceuticals Inc. · HKEX:1228 | US$120.4M | US$111.5M | n/a | 13.4× | n/a | n/a | −146.4% | n/a | n/a |
| Median of the others | US$123.7M | US$81.81M | 18.4× | 7.8× | 12.3× | 2.5× | −146.4% | 0.1× | 0.93 |
Forecasts
3 strong buy · 1 buy · 2 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 1.64 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.40 · 4 analysts
- Revenue, year to Dec 2026
- 3.86M · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Laura E. Niklason | President, Chief Executive Officer, Member of the Board |
| Dale Sander | Chief Corporate Development Officer, Chief Financial Officer & Treasurer |
| Matt Panning | Vice President, Manufacturing |
| Matt Udelhofen | Vice President, MSAT |
| Heather Connelly | Chief Quality and Regulatory Officer |
| Jim Mercadante | Chief Commercial Officer |
| Lisa Molyneux | Chief Strategy Officer |
| Sabrina Osborne | Chief People Officer |
| Shamik Parikh | Chief Medical Officer |
| Todd Rasmussen | Chief Surgical Officer |
Board
| Director | Role |
|---|---|
| Kathleen Sebelius | Chair of the Board |
| Brady W. Dougan | Member of the Board |
| C. Bruce Green | Member of the Board, Member of Audit Committee, Member of Commercial Committee |
| Diane Seimetz | Member of the Board, Member of Commercial Committee |
| Emery N. Brown | Member of the Board, Member of Nominating and Governance Committee |
| John P. Bamforth | Member of the Board, Chair of Commercial Committee |
| Keith Anthony Jones | Member of the Board, Chair of Compensation Committee |
| Laura E. Niklason | President, Chief Executive Officer, Member of the Board |
| Max Wallace | Member of the Board, Chair of Nominating and Governance Committee, Member of Compensation Committee |
| Michael T. Constantino | Member of the Board, Chair of Audit Committee |
| Susan Windham-Bannister | Member of the Board, Member of Audit Committee, Member of Commercial Committee |
Events
Calls
| Call | When | Status |
|---|---|---|
| Humacyte (NASDAQ:HUMA) Q3 2026 Earnings Call | Tue, Nov 10, 2026 · 8:00 AM ET | Replay |
| Humacyte (NASDAQ:HUMA) Q2 2026 Earnings Call | Wed, Aug 12, 2026 · 8:00 AM ET | Replay |
| Humacyte (NASDAQ:HUMA) Q1 2026 Earnings Call | Wed, May 13, 2026 · 8:00 AM ET | Replay |
| Humacyte (NASDAQ:HUMA) Q4 2025 Earnings Call | Fri, Mar 27, 2026 · 8:00 AM ET | Replay |
| Humacyte (NASDAQ:HUMA) Q3 2025 Earnings Call | Wed, Nov 12, 2025 · 8:00 AM ET | Replay |
| Humacyte (NASDAQ:HUMA) Q2 2025 Earnings Call | Mon, Aug 11, 2025 · 8:00 AM ET | Replay |
| Humacyte (NASDAQ:HUMA) Q1 2025 Earnings Call | Tue, May 13, 2025 · 8:30 AM ET | Replay |
| Humacyte (NASDAQ:HUMA) Q4 2024 Earnings Call | Fri, Mar 28, 2025 · 8:30 AM ET | Replay |
| Humacyte (NASDAQ:HUMA) Q3 2024 Earnings Call | Fri, Nov 08, 2024 · 8:30 AM ET | Replay |
| Humacyte (NASDAQ:HUMA) Q2 2024 Earnings Call | Tue, Aug 13, 2024 · 8:30 AM ET | Replay |
All 20 calls
| Call | When | Status |
|---|---|---|
| Humacyte (NASDAQ:HUMA) Q1 2024 Earnings Call | Fri, May 10, 2024 · 8:00 AM ET | Replay |
| Humacyte (NASDAQ:HUMA) Q4 2023 Earnings Call | Fri, Mar 22, 2024 · 8:00 AM ET | Replay |
| Humacyte (NASDAQ:HUMA) Q3 2023 Earnings Call | Thu, Nov 09, 2023 · 4:30 PM ET | Replay |
| Humacyte (NASDAQ:HUMA) Q2 2023 Earnings Call | Mon, Aug 14, 2023 · 8:00 AM ET | Replay |
| Humacyte (NASDAQ:HUMA) Q1 2023 Earnings Call | Fri, May 12, 2023 · 8:00 AM ET | Replay |
| Humacyte (NASDAQ:HUMA) Q4 2022 Earnings Call | Fri, Mar 24, 2023 · 8:00 AM ET | Replay |
| Humacyte (NASDAQ:HUMA) Q3 2022 Earnings Call | Thu, Nov 10, 2022 · 8:00 AM ET | Replay |
| Humacyte (NASDAQ:HUMA) Q2 2022 Earnings Call | Fri, Aug 12, 2022 · 8:00 AM ET | Replay |
| Humacyte (NASDAQ:HUMA) Q1 2022 Earnings Call | Fri, May 13, 2022 · 8:00 AM ET | Replay |
| Humacyte (NASDAQ:HUMA) Q4 2021 Earnings Call | Tue, Mar 29, 2022 · 8:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · Before open | +29.6% |
| Q2 2026 | Aug 12, 2026 · Before open | −6.3% |
| Q1 2026 | May 13, 2026 · Before open | +24.2% |
| Q4 2025 | Mar 26, 2026 | −17.9% |
| Q3 2025 | Nov 12, 2025 · Before open | −2.3% |
| Q2 2025 | Aug 11, 2025 · Before open | −29.6% |
| Q1 2025 | May 13, 2025 · Before open | +31.1% |
| Q4 2024 | Mar 20, 2025 · Before open | −3.9% |
| Q3 2024 | Nov 8, 2024 · Before open | +9.9% |
| Q2 2024 | Aug 13, 2024 · Before open | +0.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 10, 2024 · Before open | +4.0% |
| Q4 2023 | Mar 22, 2024 · Before open | −8.1% |
| Q3 2023 | Nov 9, 2023 · After close | +6.3% |
| Q2 2023 | Aug 14, 2023 · Before open | +23.6% |
| Q1 2023 | May 12, 2023 · Before open | −6.5% |
| Q4 2022 | Mar 24, 2023 · Before open | −5.8% |
| Q3 2022 | Nov 10, 2022 · Before open | +3.8% |
| Q2 2022 | Aug 12, 2022 · Before open | +5.0% |
| Q1 2022 | May 13, 2022 · Before open | +6.5% |
| Q4 2021 | Mar 29, 2022 · Before open | +5.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (June 2026) | Investor deck | 55 slides | Jun 10, 2026 |
| Corporate Update (March 2026) | Corporate update | 55 slides | Mar 19, 2026 |
| Investor Presentation (March 2025) | Investor deck | 52 slides | Mar 25, 2025 |
| Investor Presentation (February 2024) | Investor deck | 41 slides | Feb 29, 2024 |
| Investor Presentation (January 2022) | Investor deck | 37 slides | Jan 10, 2022 |
| Alpha Healthcare Acquisition — SPAC Merger (June 2021) | SPAC merger | 122 slides | Jun 7, 2021 |
| SPAC Merger (February 2021) | SPAC merger | 38 slides | Feb 17, 2021 |
| Investor Presentation | Investor deck | 57 slides |
Financings
| Raise | Date |
|---|---|
| Registered direct offering of common stock and warrants Announced: about US$60M · US$2.11 a share · 1 warrant at US$2.11 · D. Boral Capital LLC Dealers: D. Boral Capital LLC (lead) | Oct 7, 2025 |
| Public offering of common stock Announced: US$50M · US$2 a share · TD Cowen +4 Dealers: TD Cowen (co-lead), Barclays (co-lead), BTIG (co-lead), H.C. Wainwright & Co., The Benchmark Company Use of proceeds: Commercialization of SYMVESS in vascular trauma, pipeline product development, working capital and general corporate purposes | Mar 26, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Alpha Healthcare Acquisition Corp., a blank check company (SPAC). Priced at US$10.00 a unit on Sep 17, 2020.
- Price
- US$10.00 a unit
- Units offered
- 10,000,000 units
- Offering size
- US$100 million
- Underwriters' option
- Up to 1,500,000 more units
- Listing
- AHACU on the Nasdaq Capital Market
- Underwriters
- Oppenheimer & Co., Northland Capital Markets · In the order on the cover
- Units delivered
- On or about Sep 22, 2020
Steps
| Step | When |
|---|---|
| Filed publicly | Aug 4, 2020 |
| Amended twice | Newest Sep 14, 2020 |
| Shares registered with an exchange | Sep 17, 2020 |
| Declared effective by the SEC | Sep 17, 2020 |
| Final prospectus, with the price | Sep 18, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Sep 18, 2020 |
| EFFECT · Notice that a registration is effective | Sep 17, 2020 |
| CERT · Exchange's certificate of listing | Sep 17, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Sep 17, 2020 |
| S-1/A · Registration statement, amended | Sep 14, 2020 |
| S-1/A · Registration statement, amended | Sep 1, 2020 |
| S-1 · Registration statement | Aug 4, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Sep 18, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.04M | 0 | 0 | 1.56M | 1.26M | 1.49M | 6.19M |
| Cost of revenue | 9.70M | 0 | 76.5M | 8.26M | 61.3M | 54.1M | 75.6M |
| Gross profit | -15.0M | -7.19M | -76.5M | -6.69M | -60.1M | -52.6M | -69.4M |
| Research and development | 69.3M | 88.6M | 76.5M | 63.3M | 61.3M | 54.1M | 75.6M |
| Selling, general and administrative | 31.2M | 25.8M | 23.4M | 22.9M | 21.0M | 11.9M | 16.3M |
| Operating income | -108.1M | -114.4M | -100.0M | -84.6M | -81.2M | -64.6M | -85.7M |
| Depreciation and amortization | 5.33M | 5.10M | 5.66M | 6.15M | 6.18M | 6.29M | 6.75M |
| EBITDA | -102.8M | -109.3M | -94.4M | -78.4M | -75.0M | -58.3M | -78.9M |
| Interest expense | 11.3M | 9.28M | 6.60M | 6.20M | 4.35M | 2.20M | 2.30M |
| Income before tax | -40.8M | -148.7M | -110.8M | -12.0M | -26.5M | -66.5M | -85.4M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | |
| Net income | -40.8M | -148.7M | -110.8M | -12.0M | -26.5M | -66.5M | -85.4M |
| Earnings per share, basic | -0.26 | -1.26 | -1.07 | -0.12 | -0.66 | -11.54 | -0.83 |
| Earnings per share, diluted | -0.26 | -1.26 | -1.07 | -0.12 | -0.66 | -11.54 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 50.5M | 44.9M | 80.4M | 149.8M | 217.5M | 39.9M | 93.7M |
| Short-term investments | 0 | 2.11M | 8.00M | 0 | |||
| Receivables | 441.0K | 0 | 0 | 31.0K | 176.0K | 113.0K | 601.0K |
| Inventory | 13.6M | 0 | -31.0K | 1 | 1 | 1 | |
| Current assets | 67.8M | 47.9M | 83.3M | 154.2M | 229.3M | 41.4M | 95.0M |
| Property, plant and equipment | 18.5M | 23.1M | 26.8M | 30.0M | 35.0M | 41.0M | 73.7M |
| Total assets | 116.4M | 137.9M | 128.2M | 204.3M | 286.5M | 106.7M | 168.7M |
| Accounts payable | 5.40M | 4.49M | 6.49M | 1.59M | 2.09M | 2.27M | 3.27M |
| Current liabilities | 18.4M | 20.0M | 18.4M | 19.6M | 11.1M | 11.2M | 10.8M |
| Long-term debt | 35.4M | 38.6M | 20.3M | 27.4M | 822.0K | ||
| Total debt | 35.4M | 0 | 57.5M | 50.1M | 30.0M | 28.9M | 28.7M |
| Total liabilities | 113.3M | 190.5M | 114.7M | 87.4M | 164.4M | 36.0M | 36.5M |
| Shareholders' equity | 3.11M | -52.7M | 13.5M | 116.9M | 122.2M | -350.3M | 132.2M |
| Shares outstanding | 193.0M | 130.0M | 103.7M | 103.2M | 103.0M | 5.82M | 103.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -105.0M | -98.1M | -73.3M | -71.1M | -81.2M | -55.6M | -71.8M |
| Capital spending | -884.0K | -1.57M | -2.28M | -1.05M | -220.0K | -318.0K | -8.13M |
| Free cash flow | -105.9M | -99.7M | -75.6M | -72.2M | -81.4M | -55.9M | -79.9M |
| Cash from investing | -884.0K | -1.57M | -173.0K | 4.84M | -8.22M | -268.0K | -8.13M |
| Cash from financing | 61.5M | 114.2M | 4.51M | -1.45M | 267.0M | 2.05M | -74.0K |
| Dividends paid | 0 | 0 | |||||
| Share buybacks | 708.0K | 535.0K | 243.0M | ||||
| Change in cash | -44.4M | 14.5M | -69.0M | -67.7M | 177.6M | -53.8M | -80.0M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 28, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 28, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 28, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Sep 15, 2026 | Insider trade | SEC |
| 25-NSE | Aug 25, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 18, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2026 | Results | SEC |
| 8-K · Current report | Jul 31, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 28, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 22, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 15, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jun 11, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Jun 10, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 10, 2026 | Current report | SEC |
| 8-K · Current report | Jun 9, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jun 5, 2026 | Current report | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 18, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | May 14, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2026 | Current report | SEC |
| DEF 14A · Proxy statement | Apr 28, 2026 | Meeting notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Apr 24, 2026 | Material contract | SEC |
| PRE 14A · Preliminary proxy statement | Apr 17, 2026 | Meeting notice | SEC |
| 10-K · Annual report | Mar 27, 2026 | Annual report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 24, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 19, 2026 | Material contract | SEC |
| 424B3 · Prospectus | Mar 19, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 19, 2026 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 9, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Dec 16, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Dec 16, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 15, 2025 | Material contract | SEC |
| 8-K · Current report | Dec 15, 2025 | Current report | SEC |
| 424B3 · Prospectus | Dec 15, 2025 | Offer document | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 26, 2025 | Current report | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 16, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Oct 7, 2025 | Material contract | SEC |
| 424B3 · Prospectus | Oct 7, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 23, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Sep 22, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Sep 18, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 17, 2025 | Material contract | SEC |
| UPLOAD · Letter from the SEC | Sep 17, 2025 | Other filings | SEC |
| S-3 · Registration statement | Sep 12, 2025 | Offer document | SEC |
| 4 · Change in ownership | Aug 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 20, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 19, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 18, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 11, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2025 | Results | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2025 | Meeting outcome | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 22, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 17, 2025 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Apr 17, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 8, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 31, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 28, 2025 | Results | SEC |
| 8-K · Current report | Mar 27, 2025 | Current report | SEC |
| 8-K · Current report | Mar 26, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Mar 26, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Mar 25, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 25, 2025 | Current report | SEC |
| 4 · Change in ownership | Jan 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 20, 2024 | Current report | SEC |
| 4 · Change in ownership | Dec 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 20, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 20, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 19, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 18, 2024 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 18, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 14, 2024 | Material contract | SEC |
| 424B3 · Prospectus | Nov 14, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 8, 2024 | Quarterly report | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 8, 2024 | Results | SEC |
| 8-K · Current report | Oct 28, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Oct 24, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 7, 2024 | Material contract | SEC |
| 424B3 · Prospectus | Oct 4, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Sep 25, 2024 | Offer document | SEC |
| 8-K · Current report | Sep 24, 2024 | Material contract | SEC |
| 4 · Change in ownership | Sep 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 10, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 10, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 9, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Sep 3, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 29, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 29, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 28, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 27, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 27, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 15, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| UPLOAD · Letter from the SEC | Aug 13, 2024 | Other filings | SEC |
| 8-K · Current report | Aug 13, 2024 | Results | SEC |
| CORRESP · Letter to the SEC | Aug 6, 2024 | Other filings | SEC |
| 8-K · Current report | Jul 31, 2024 | Current report | SEC |
| UPLOAD · Letter from the SEC | Jul 23, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 17, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 17, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 13, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 12, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Jun 4, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 4, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
This page holds 200 of 506 filings. Open Filings
Cap table
Built by 6ix from Humacyte, Inc.’s releases · as of Nov 10, 2026
- Common shares
- 277,798,105
- Fully diluted
- 277,798,105
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 277,798,105 | Nov 10, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 10, 2026 | 277,798,105 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Rajiv Shukla Other companies: Longevity Health Holdings, Inc. (Chairman and CEO, Director · Jul 26, 2021 – Oct 11, 2024 · Past); Constellation Alpha Capital Corp (CEO & Chairman, Director · Jun 19, 2017 – Jun 23, 2017 · Past) | Director · Sep 17, 2020 – Jun 15, 2023 · Past |
| Patrick A Sturgeon Other companies: Longevity Health Holdings, Inc. (Director · Jul 26, 2021 – Oct 11, 2024 · Past) | CFO · Sep 17, 2020 – Sep 17, 2020 · Past |
| Brady W. Dougan | Director · Since at least Aug 26, 2021 |
| Bruce A Springer | Director · Sep 17, 2020 – Sep 17, 2020 · Past |
| C. Bruce Green | Member of the Board, Member of Audit Committee, Member of Commercial Committee · Since at least Nov 5, 2026 |
| Charles Bruce Green | Director · Since at least Sep 15, 2022 |
| Dale Sander | Chief Corporate Development Officer, Chief Financial Officer & Treasurer · Since at least Aug 26, 2021 |
| Diane Seimetz | Member of the Board, Member of Commercial Committee · Since at least Nov 5, 2026 |
| Emery N. Brown | Member of the Board, Member of Nominating and Governance Committee · Since at least Nov 5, 2026 |
| Gordon M Binder | Director · Aug 26, 2021 – May 15, 2024 · Past |
All 31 people
| Person | Seat |
|---|---|
| Heather Connelly | Chief Quality and Regulatory Officer · Since at least Nov 4, 2026 |
| Heather Ledbetter Prichard | Chief Operating Officer · Aug 26, 2021 – Jan 21, 2025 · Past |
| Jim Mercadante | Chief Commercial Officer · Since at least Oct 15, 2026 |
| John P. Bamforth | Director · Since at least Jun 11, 2024 |
| Kathleen Sebelius | Director · Since at least May 19, 2026 |
| Keith Anthony Jones | Member of the Board, Chair of Compensation Committee · Since at least Jun 11, 2024 |
| Laura E. Niklason | President, CEO and Director, Director · Since at least Jun 12, 2025 |
| Lisa Molyneux | Chief Strategy Officer · Since at least Nov 4, 2026 |
| Matt Panning | Vice President, Manufacturing · Since at least Nov 4, 2026 |
| Matt Udelhofen | Vice President, MSAT · Since at least Nov 4, 2026 |
| Max Wallace | Director · Since at least Nov 21, 2023 |
| Michael T. Constantino | Director · Since at least Aug 26, 2021 |
| Paul Brian Kuznik | Director · Since at least Sep 22, 2026 |
| Rick McElheny | Senior Vice President of Business Development · Mar 26, 2026 – Nov 5, 2026 · Past |
| Sabrina Osborne | Chief People Officer · Since at least Nov 4, 2026 |
| Shamik Parikh | Chief Medical Officer · Since at least May 20, 2026 |
| Susan Windham-Bannister | Member of the Board, Member of Audit Committee, Member of Commercial Committee · Since at least Nov 5, 2026 |
| Todd Pope | Director · Since at least Jun 12, 2025 |
| Todd Rasmussen | Chief Surgical Officer · Since at least Aug 12, 2026 |
| William Edward Tente | Chief Regulatory Officer · Aug 26, 2021 – Aug 26, 2021 · Past |
| Yang Cao | Chief Regulatory Officer · Sep 19, 2022 – Jan 21, 2025 · Past |
Log in to ask 6ix AI your own questions about Humacyte, Inc.